Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis

Thomas F Scott, Bernd C Kieseier, Scott D Newsome, Douglas L Arnold, Xiaojun You, Serena Hung, Bjoern Sperling, Thomas F Scott, Bernd C Kieseier, Scott D Newsome, Douglas L Arnold, Xiaojun You, Serena Hung, Bjoern Sperling

Abstract

Background: Subcutaneous peginterferon beta-1a every 2 weeks significantly affects clinical outcomes in patients with relapsing-remitting multiple sclerosis (RRMS).

Objectives: To explore relationships between relapses and worsening of disability in patients with RRMS, and assess the treatment effect of peginterferon beta-1a on relapse recovery.

Methods: Post-hoc analysis of the 2-year, randomized, double-blind, parallel-group, Phase 3 ADVANCE study. The severity of relapses, proportion of patients with relapses associated with residual disability (onset of 24-week confirmed disability progression (CDP) within 90 days following a relapse), and persistence of changes in Functional Systems Scores, were compared between treatment groups.

Results: Subcutaneous peginterferon beta-1a every 2 weeks significantly reduced the proportion of patients experiencing relapse associated with CDP over 2 years (6.6%, compared with 15.1% of patients who received placebo in Year 1; p = 0.02). Reduction in relapses associated with residual disability was greater than the treatment effect on overall relapse rate, and occurred despite similar relapse severity across treatment groups.

Conclusions: The beneficial effect of peginterferon beta-1a on risk of CDP may be attributable to the combination of an overall reduction in the risk of relapses and improvement in recovery from relapses, thus limiting further disability progression.

Trial registration: ClinicalTrials.gov identifier: NCT00906399.

Keywords: Clinical trial; peginterferon beta-1a; relapsing–remitting multiple sclerosis.

Figures

Figure 1.
Figure 1.
Schema for percentage of relapses leading to CDP. Red arrow represents onset of CDP and blue arrows represent examples of patients with relapses associated or not associated with the CDP. CDP: confirmed disability progression.
Figure 2.
Figure 2.
Proportion of patients experiencing relapses with incomplete recovery (onset of 24-week CDP within 90 days following relapse) over 2 years: (a) all patients with relapse, by Year 1 treatment assignment; (b) all patients with relapse who entered Year 2, by Year 2 treatment assignment.

References

    1. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 2006; 63: 1686–1691.
    1. Scott TF. Are we studying MS relapses in the right way? Mult Scler Relat Disord 2013; 2: 2–3.
    1. Skoog B, Tedeholm H, Runmarker B, et al. Continuous prediction of secondary progression in the individual course of multiple sclerosis. Mult Scler Relat Disord 2014; 3: 584–592.
    1. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528–1532.
    1. Hirst C, Ingram G, Pearson O, et al. Contribution of relapses to disability in multiple sclerosis. J Neurol 2008; 255: 280–287.
    1. O’Connor PW, Lublin FD, Wolinsky JS, et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol 2013; 260: 2472–2480.
    1. Lublin FD, Cutter G, Giovannoni G, et al. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Mult Scler Relat Disord 2014; 3: 705–711.
    1. Calabresi PA, Kieseier BC, Arnold DL, et al. on behalf of the ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014; 13: 657–665.
    1. Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 2015; 21: 1025–1035.
    1. Biogen. Plegridy® (package insert). Cambridge, MA: Biogen, 2014.
    1. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.
    1. Berger VW. Does the Prentice criterion validate surrogate endpoints? Stat Med 2004; 23: 1571–1578.
    1. Scott TF, You X, Mann MK. Incomplete relapse recovery and sustained disability progression in multiple sclerosis. In: Fifth cooperative meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis, Orlando, FL, 29 May–1 June 2013 Orlando, FL, 29 May–1 June 2013.
    1. Sorman MP, Vollmer TL, Comi G, et al. Laquinimod effect on confirmed disability progression: minimal mediation by relapse or T2 lesions reduction. In: Meeting of the European Committee for Treatment and Research in Multiple Sclerosis, Boston, MA, 10–13 September 2014 2014.
    1. Scott TF, You X, Foulds P. Functional system scores provide a window into disease activity occurring during a multiple sclerosis treatment trial. Neurol Res 2011; 33: 549–552.
    1. Gold R, Kappos L, Arnold DL, et al. on behalf of the DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098–1107.
    1. Fox RJ, Miller DH, Phillips JT, et al. on behalf of the CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087–1097.
    1. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278–286.
    1. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010; 133: 1914–1929.
    1. Newsome SD, Guo S, Altincatal A, et al. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis. Mult Scler Relat Disord 2015; 4: 350–357.
    1. You X, Scott T, Shang S, et al. Evaluation of relapses as a surrogate marker for confirmed disability progression in relapsing-remitting multiple sclerosis patients treated with peginterferon beta-1a using the Prentice criteria. In: First congress of the European Association of Neurology, Berlin, Germany, 20–23 June 2015 2015.
    1. Scott TF, Getting EJ, Hackett CT, et al. Specific clinical phenotypes in relapsing multiple sclerosis: the impact of relapses on long-term outcomes. Mult Scler Relat Disord 2016; 5: 1–6.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere